MedPath

FDA Grants Fast Track Designation for Abenacianine in Lung Cancer Surgery

The FDA has granted fast track designation to abenacianine, a drug aimed at enhancing the visualization of lung tumors during minimally invasive surgery, marking a significant advancement in lung cancer treatment.

The FDA has granted fast track designation for abenacianine, a promising development in the field of lung cancer treatment. This designation is aimed at helping surgeons better visualize lung tumors during minimally invasive surgery, potentially improving surgical outcomes and patient recovery times. The fast track process is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need, highlighting the importance of abenacianine in the ongoing fight against lung cancer.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Updates: Approvals and Designations in Leukemia, Prostate Cancer, and Melanoma

Capivasertib plus abiraterone and ADT shows improved radiographic progression-free survival in PTEN-deficient metastatic hormone-sensitive prostate cancer.
LBS-007 receives FDA fast track designation for acute myeloid leukemia treatment based on promising early response data from a phase 1/2 trial.

CAR-T Therapy Yescarta and Quizartinib Approved for Blood Cancers on NHS Scotland

The Scottish Medicines Consortium (SMC) has approved axicabtagene ciloleucel (Yescarta) for diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).
Yescarta, a CAR-T therapy, offers a new treatment option for patients whose cancer has relapsed or is refractory to first-line treatments, improving their chances of a cure.

Nebraska Medicine Pioneers Commercial CAR-T Cell Therapy for Mantle Cell Lymphoma

Nebraska Medicine successfully administered commercial CAR-T cell therapy to a patient with mantle cell lymphoma, marking a global first.
The CAR-T cell therapy re-engineered the patient's immune cells to target and destroy cancer cells, showing promise in cancer treatment.

Advancements in Oncology: CAR-T Therapy for Myeloma, Cologuard Plus Approval, and NSCLC Treatment

HBI0101, a novel BCMA-directed CAR T-cell therapy, shows high efficacy and manageable safety in relapsed/refractory multiple myeloma patients, offering a promising treatment option.
Cologuard Plus receives FDA approval as a noninvasive stool DNA test for colorectal cancer screening in adults 45 and older, demonstrating improved detection rates.

FDA Approvals and Designations in Oncology: September 2024

The FDA approved a subcutaneous formulation of atezolizumab (Tecentriq Hybreza) for various cancers, offering a more convenient administration option for patients.
Ribociclib (Kisqali) gained approval for early-stage breast cancer, expanding treatment options for this disease and showing improved invasive disease-free survival.

Recent Advances in Oncology: FDA Approvals, Promising Therapies, and Evolving Treatment Strategies

The FDA approved inavolisib plus palbociclib/fulvestrant for endocrine-resistant, PIK3CA-mutated, HR+/HER2- advanced breast cancer, significantly improving progression-free survival.
Zolbetuximab combined with chemotherapy received FDA approval for first-line treatment of CLDN18.2+ gastric or GEJ adenocarcinoma, based on positive results from SPOTLIGHT and GLOW trials.

First in Arizona Commercial Use of New Cancer Therapy Shows Promising Results

A Phoenix woman becomes the first in Arizona to undergo a newly FDA-approved cancer therapy, showing significant tumor shrinkage and expressing hope for the future.

Teclistamab Shows Promise in Heavily Pretreated Multiple Myeloma

In the MajesTEC-1 trial, teclistamab demonstrated a nearly two-thirds partial response rate in patients with relapsed or refractory multiple myeloma.
The median progression-free survival with teclistamab was approximately 11 months, with responses lasting a median of 18 months in heavily pretreated patients.

Subcutaneous Isatuximab Plus Pd Shows Promise in R/R Multiple Myeloma Treatment

Recent clinical trials reveal that subcutaneous isatuximab combined with Pd meets coprimary endpoints and is noninferior to IV administration in treating relapsed/refractory multiple myeloma, marking a significant advancement in care.

FDA Grants Fast Track Status to BBO-8520 for KRAS G12C-Mutated NSCLC

The FDA has granted fast track designation to BBO-8520, an oral agent under investigation for treating KRAS G12C-mutated metastatic non-small cell lung cancer.
This designation aims to expedite the development and review of BBO-8520, addressing an unmet need in previously treated NSCLC patients.

Reference News

[1]
CURE - Oncology & Cancer News for Patients & Caregivers
curetoday.com · Jul 24, 2020

Aswita Tan-McGrory shares her journey of being diagnosed with multiple myeloma and undergoing a stem cell transplant. Th...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy